I take it every other day...talk to your doctor

"Recent studies suggest a potential role for alpha-lipoic acid (ALA) in modulating prostate cancer cell growth and progression. Specifically, research indicates that ALA treatment can significantly reduce the viability, migration, and invasion of prostate cancer cell lines in a dose-dependent manner. This effect may be linked to several cellular processes:
Autophagy inhibition: ALA has been shown to inhibit autophagy, a process in which cells recycle components to support growth, particularly in conditions like nutrient deprivation. By inhibiting autophagy, ALA could hinder the survival and proliferation of cancer cells.
Induction of apoptosis: ALA can trigger programmed cell death (apoptosis) in prostate cancer cells through an increase in reactive oxygen species (ROS) levels and activation of the HIF-1α/JNK/Caspase-3 pathway.
Modulation of epithelial-mesenchymal transition (EMT): ALA has been observed to inhibit migration and invasion of prostate cancer cells by counteracting EMT, a process that enables cancer cells to become more invasive and metastatic. This effect is evidenced by the increased expression of E-cadherin and decreased levels of vimentin and N-cadherin after ALA treatment.
Impact on bone health in cases of metastasis: Beyond its effects on cancer cells directly, ALA treatment has also been shown to improve bone health in the context of prostate cancer bone metastases by reducing the differentiation of bone cells (osteoblasts and osteoclasts).